Kevin Kalinsky, MD, MS, Emory University Hospital, Atlanta, GA, discusses the ongoing debate regarding the necessity of ovarian suppression in patients with HER2-positive, hormone receptor-positive (HR+/HER2+) breast cancer. Ovarian suppression enhances the efficacy of tamoxifen, particularly in patients with HER2+ disease, as shown in the HERA trial (NCT00045032). Despite this, challenges remain, including medication adherence and the evolving landscape of HER2-targeted therapies. Ovarian suppression is recommended in high-risk patients, especially those with significant residual disease after neoadjuvant HER2 therapy and chemotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
